アブストラクト
| Title | No.2 副作用管理 : 悪心・嘔吐 |
|---|---|
| Subtitle | シリーズ : 抗がん薬治療の副作用 |
| Authors | 飯原大稔, 鈴木昭夫 |
| Authors (kana) | |
| Organization | 岐阜大学医学部附属病院薬剤部 |
| Journal | 日本臨床腫瘍薬学会雑誌 |
| Volume | 13 |
| Number | |
| Page | 6-21 |
| Year/Month | 2020 / 1 |
| Article | 報告 |
| Publisher | 日本臨床腫瘍薬学会 |
| Abstract | 「POINT」・抗がん薬による悪心・嘔吐の発現機序を理解する. ・悪心・嘔吐の分類を理解する. ・抗がん薬の催吐性を理解する. ・最新の制吐薬適正使用ガイドラインを理解する. 「はじめに」がん化学療法による悪心・嘔吐(Chemotherapy Induced Nausea and Vomiting: CINV)は, かつては患者が治療を受けるうえで最も辛いと訴える副作用であった. 重篤なCINVは, 患者の生活の質を損なうとともに治療へのアドヒアランスを低下させ, その後の治療を継続することが困難となることもある. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J : Patient perceptions of the side-effects of chemotherapy : The influence of 5HT3 antagonists, Br J Cancer 1997 ; 76(8) : 1055-1061.
- 2) Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D : Changing patient perceptions of the side effects of cancer chemotherapy, Cancer 2002 ; 95(1) : 155-163.
- 3) 日本癌治療学会 : 制吐薬適正使用ガイドライン 2010年5月, 第1版, 金原出版
- 4) Navari RM, Aapro M : Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting, N Engl J Med 2016 ; 374(14) : 1356-1367.
- 5) Rojas C, Raje M, Tsukamoto T, Slusher BS : Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis, Eur J Pharmacol 2014 ; 722 : 26-37.
残りの30件を表示する
- 6) Grunberg SM, Hesketh PJ : Control of chemotherapy-induced emesis, N Engl J Med 1993 ; 329(24) : 1790-1796.
- 7) Kamen C, Tejani MA, Chandwani K, Janelsins M, Peoples AR, Roscoe JA, Morrow GR : Anticipatory nausea and vomiting due to chemotherapy, Eur J Pharmacol 2014 ; 722 : 172-179.
- 8) Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM : Proposal for classifying the acute emetogenicity of cancer chemotherapy, J Clin Oncol 1997 ; 15(1) : 103-109.
- 9) NCCN clinical practice guidelines in oncology : Antiemesis Version 1.2019 https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
- 10) Tavorath R, Hesketh PJ : Drug treatment of chemotherapy-induced delayed emesis, Drugs 1996 ; 52(5) : 639-648.
- 11) 有害事象共通用語規準v5.0 日本語訳JCOG版 http://www.jcog.jp/doctor/tool/CTCAEv5J_20190905_v22_1.pdf
- 12) NCI-PRO-CTCAE(TM) ITEMS-JAPANESE Item Library Version 1.0 https://healthcaredelivery.cancer.gov/pro-ctcae/pro-ctcae_japanese.pdf
- 13) MASCC Antiemesis Tool(C)(MAT) https://www.mascc.org/mat
- 14) Brafford MV, Glode A : Olanzapine : An antiemetic option for chemotherapy-induced nausea and vomiting, J Adv Pract Oncol 2014 ; 5 : 24-29.
- 15) Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL : Olanzapine for the prevention of chemotherapy-Induced nausea and vomiting, N Engl J Med 2016 ; 375(2) : 134-142.
- 16) Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y : Olanzapine 5mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting(J-FORCE) : A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol 2019 ; Epub ahead of print.
- 17) Navari RM, Gray SE, Kerr AC : Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting : A randomized phase III trial, J Support Oncol 2011 ; 9(5) : 188-195.
- 18) Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F : Italian Group for Antiemetic Research Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis : A randomized, double-blind study, Ann Oncol 2015 ; 26(6) : 1248-1253.
- 19) Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M : Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer : A randomized double-blind study, J Clin Oncol 2014 ; 32(2) : 1101-1106.
- 20) Jordan K, Blattermann L, Hinke A, Muller-Tidow C, Jahn F : Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-A systematic review and meta-analysis, Support Care Cancer 2018 ; 26(1) : 21-32.
- 21) Italian Group for Antiemetic Research : Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy, N Engl J Med 2000 ; 342(21) : 1554-1559.
- 22) Geling O, Eichler HG : Should 5-hydroxy-tryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications, J Clin Oncol 2005 ; 23(6) : 1289-1294.
- 23) Navari RM, Nagy CK, Gray SE : The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, Support Care Cancer 2013 ; 21(6) : 1655-1663.
- 24) Aapro M, Fabi A, Nole F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F : Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy, Ann Oncol 2010 ; 21(5) : 1083-1088.
- 25) Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E ; Italian Trials in Medical Oncology Group : Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy : A randomized, multicenter, phase III trial, Support Care Cancer 2011 ; 19(8) : 11217-11225.
- 26) Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y : Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron, Cancer Sci 2015 ; 106(7) : 891-895.
- 27) Furukawa N, Kanayama S, Tanase Y, Ito F : Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin, Support Care Cancer 2015 ; 23(11) : 3317-3322.
- 28) Kosaka Y, Tanino H, Sengoku N, Minatani N, Kikuchi M, Nishimiya H, Waraya M, Katoh H, Enomoto T, Sato T, Kuranami M, Watanabe M : Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy, Support Care Cancer 2016 ; 24(3) : 1405-1411.
- 29) Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S, Komatsu Y, Celio L, Aapro M : One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting : a systematic review and individual patient data-based meta-analysis, Oncologist 2019 ; 24(12) : 1593-1600.
- 30) Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M, Tsugawa K, Kojima Y, Furuya N, Matsuzaki K, Fukuda M, Sugae S, Ohta I, Arioka H, Tokuda Y, Narui K, Tsuboya A, Suda T, Morita S, Boku N, Yamanaka T, Nakajima TE : Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy, J Clin Oncol 2018 ; 36(10) : 1000-1006.
- 31) Minatogawa H, Izawa N, Kawaguchi T, Miyaji T, Yokomizo A, Horie Y, Shimomura K, Honda K, Morita H, Hida N, Tsuboya A, Tsuda T, Iihara H, Ohno Y, Yamaguchi T, Nakajima T : Phase III study of comparing dexamethasone on day 1 with day 1-4 with combined neurokinin-1 receptor antagonist, palonosetron and olanzapine in cisplatin-based chemotherapy : Spared trial MASCC/ISOO International Symposium on Supportive Care in Cancer, San Francisco, 2019
- 32) Tsuneizumi M, Saito M, Ogata H, Kutomi G, Kawai Y, Hosoya K, Sugizaki K, Katsumata N, Kitabatake T, Senuma K, Suda M, Miura K, Kurata M, Uomori T, Nitta Y, Sahara E, Matsuzawa H, Yonemoto N, Matsuoka J. : Trial of antiemetic triplet therapy comparing palonosetron and granisetron in breast cancer patients receiving ac chemotherapy : Double blind randomised comparative phase iii study MASCC/ISOO 2016, abstr. eP022
- 33) Matsumoto K, Takahashi M, Sato K, Takano T, Ryushima Y, Doi M, Aogi K, Fujiwara K, Tamura K, Hosoda M, Tokunaga S, Makiyama A, Miyamoto K, Hozumi Y, Yanagihara K, Imamura CK, Chiba Y, Nakamura S, Saeki T, WJOG : West Japan Oncology Group. Palonosetron or granisetron for prevention of CINV in patients with breast cancer receiving dexamethasone and fosaprepitant following anthracycline plus cyclophosphamide(AC) regimen. ASCO 2015, abstr. 9598
- 34) Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martinez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD : Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer, J Clin Oncol 2018 ; 36(28) : 2872-2878.
- 35) Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM : Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications, J Clin Oncol 2019 ; 37(22) : 1927-1934.
